TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Perspectives and Testing Uptake With Abbreviated Versus Standard HIV Consenting in the Prenatal Setting: A Randomized-Controlled, Non-Inferiority Trial
Brief Summary: The purpose of the study is to determine whether an abbreviated pretest/post-test CDC recommended counseling is as equally acceptable to prenatal patients as the standard strategy using prenatal care nurses and medical providers at San Francisco General Hospital \[SFGH\]).


Options:
A: Arm Label: Abbreviated Consenting; Type: EXPERIMENTAL; Interventions: Procedure: Abbreviated HIV test counseling | Arm Label: Standard Consenting; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Abbreviated HIV test counseling; Assigned to Arm(s): Abbreviated Consenting
B: Arm Label: E-CAU with Group Problem Management Plus (PM+); Type: EXPERIMENTAL; Interventions: Behavioral: Problem Management Plus (PM+) | Arm Label: Enhanced care as usual (E-CAU) only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Problem Management Plus (PM+); Assigned to Arm(s): E-CAU with Group Problem Management Plus (PM+)
C: Arm Label: Patient Navigation Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Navigation | Arm Label: Standard of Care - No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient Navigation; Assigned to Arm(s): Patient Navigation Intervention
D: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Perspectives and Testing Uptake With Abbreviated Versus Standard HIV Consenting in the Prenatal Setting: A Randomized-Controlled, Non-Inferiority Trial
Brief Summary: The purpose of the study is to determine whether an abbreviated pretest/post-test CDC recommended counseling is as equally acceptable to prenatal patients as the standard strategy using prenatal care nurses and medical providers at San Francisco General Hospital \[SFGH\]).


Options:
A: Arm Label: Abbreviated Consenting; Type: EXPERIMENTAL; Interventions: Procedure: Abbreviated HIV test counseling | Arm Label: Standard Consenting; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Abbreviated HIV test counseling; Assigned to Arm(s): Abbreviated Consenting
B: Arm Label: Patient decision aids; Type: EXPERIMENTAL; Interventions: Other: Patient decision aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient decision aid; Assigned to Arm(s): Patient decision aids
C: Arm Label: Contraceptive Decision Support Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Contraceptive Decision Support Tool | Arm Label: Usual Care (Control); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Contraceptive Decision Support Tool; Assigned to Arm(s): Contraceptive Decision Support Tool
D: Arm Label: Control: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DT LVAD Decision Support Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: DT LVAD Decision Support Intervention | Intervention Type: BEHAVIORAL; Name: DT LVAD Decision Support Intervention; Assigned to Arm(s): DT LVAD Decision Support Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II,Multicenter,Randomized,Double-blind,Cross-over Study of Palonosetron Compared With Granisetron in Prevention of Chemotherapy-induced Nausea and Vomiting in Asian Population
Brief Summary: The purpose of this study is to determine whether palonosetron is tolerate and effective in preventing chemotherapy-induced nausea and vomiting in oriental population. The study is comparing the safety and efficacy of palonosetron with granisetron, a frequently used antiemetic in China.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Placebo, Drug: Ondansetron | Arm Label: Single Dose IV; Type: EXPERIMENTAL; Interventions: Drug: Casopitant, Drug: Dexamethasone, Drug: Ondansetron | Intervention Type: DRUG; Name: Casopitant; Assigned to Arm(s): Single Dose IV | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Control, Single Dose IV | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Control, Single Dose IV
B: Intervention Type: DRUG; Name: Palonosetron; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): N/A
C: Arm Label: Aprepitant; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant/Ramosetron/Dexamethasone | Intervention Type: DRUG; Name: Aprepitant/Ramosetron/Dexamethasone; Assigned to Arm(s): Aprepitant
D: Arm Label: Fosaprepitant dimeglumine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fosaprepitant dimeglumine | Arm Label: Saline water; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fosaprepitant dimeglumine; Assigned to Arm(s): Fosaprepitant dimeglumine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Saline water

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2
B: Arm Label: neutral protamine insulin, metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir | Arm Label: insulin detemir, metformin; Type: EXPERIMENTAL; Interventions: Drug: neutral protamine insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): neutral protamine insulin, metformin | Intervention Type: DRUG; Name: neutral protamine insulin; Assigned to Arm(s): insulin detemir, metformin
C: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
D: Arm Label: Glargine insulin; Type: EXPERIMENTAL; Interventions: Drug: Glargine insulin | Arm Label: NPH insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin | Intervention Type: DRUG; Name: Glargine insulin; Assigned to Arm(s): Glargine insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): NPH insulin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.


Options:
A: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin
B: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
C: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
D: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, 300 U/ml, Drug: Background Therapy | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin glargine, 100 U/ml, Drug: Insulin detemir, Drug: Background Therapy | Intervention Type: DRUG; Name: Insulin glargine, 300 U/ml; Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: Insulin glargine, 100 U/ml; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Insulin detemir; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Background Therapy; Assigned to Arm(s): Standard of Care, Toujeo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Thoracic Spine Thrust Mobilization: A Randomized Clinical Trial
Brief Summary: Recently a clinical prediction rule (CPR) has been developed that identifies patients with neck pain who are likely to respond rapidly and dramatically to thoracic spine thrust manipulation and an active range of motion exercise. Although the initial predictor variables identified during the development of a thoracic spine manipulation CPR seem to have adequate face validity, there is no guarantee that these factors will persist in a different group of patients, even ones with similar characteristics as those used in the initial exploratory study. The purpose of this follow-up study in which patients will be randomly assigned to receive thoracic spine thrust manipulation followed by therapeutic exercises or therapeutic exercise alone will be to investigate the validity of the previously developed CPR. If the CPR is indeed meaningful, patients who are positive on the CPR and receive thoracic spine thrust manipulation should experience improved outcomes compared to patients who are negative on the CPR and receive thoracic spine manipulation, and compared to patients who are positive on the CPR but receive the intervention believed to be effective for another subgroup of patients with neck pain.


Options:
A: Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: manual therapy, Other: exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: exercise | Intervention Type: OTHER; Name: manual therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal manipulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Spinal manipulation + exercises | Intervention Type: OTHER; Name: spinal manipulation; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Spinal manipulation + exercises; Assigned to Arm(s): 3
D: Arm Label: Training; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Reference; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reference | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Training | Intervention Type: BEHAVIORAL; Name: Reference; Assigned to Arm(s): Reference

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia
Brief Summary: The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.


Options:
A: Intervention Type: DRUG; Name: Atorvastatin, 10mg, 20mg, 40mg; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Atorvastatin Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 3
D: Arm Label: LCP-AtorFen; Type: EXPERIMENTAL; Interventions: Drug: LCP-AtorFen | Arm Label: atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: fenofibrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: fenofibrate | Intervention Type: DRUG; Name: LCP-AtorFen; Assigned to Arm(s): LCP-AtorFen | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin | Intervention Type: DRUG; Name: fenofibrate; Assigned to Arm(s): fenofibrate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.
Brief Summary: This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.


Options:
A: Arm Label: Brivaracetam (BRV) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam (BRV) 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Lorazepam (LZP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam (BRV) 100 mg, Brivaracetam (BRV) 200 mg | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam (LZP)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 100 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Arm Label: Brivaracetam 200 mg/ day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam, Drug: Antiepileptic drugs with market authorization available per country | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/ day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 200 mg/ day | Intervention Type: DRUG; Name: Antiepileptic drugs with market authorization available per country; Assigned to Arm(s): Brivaracetam 100 mg/ day, Brivaracetam 200 mg/ day, Placebo
D: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.
Brief Summary: This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-blind-placebo-controlled and Open-label-Sevelamer Hydrochloride-controlled, Dose-ranging Study for ASP1585 in Patients With Chronic Kidney Disease(CKD) and Hyperphosphatemia on Hemodialysis
Brief Summary: To evaluate the superiority to placebo, dose-responsibility and safety.


Options:
A: Arm Label: ASP1585 dose #1; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #2; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #3; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sevelamer hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer hydrochloride | Intervention Type: DRUG; Name: ASP1585; Assigned to Arm(s): ASP1585 dose #1, ASP1585 dose #2, ASP1585 dose #3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): Sevelamer hydrochloride
B: Arm Label: Renvela; Type: EXPERIMENTAL; Interventions: Drug: Renvela | Arm Label: Etalpha; Type: EXPERIMENTAL; Interventions: Drug: Etalpha | Intervention Type: DRUG; Name: Renvela; Assigned to Arm(s): Renvela | Intervention Type: DRUG; Name: Etalpha; Assigned to Arm(s): Etalpha
C: Arm Label: K2CG chewing gum (20 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (20mg chitosan) | Arm Label: K2CG chewing gum (60 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (60mg chitosan) | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: K2CG chewing gum (20mg chitosan); Assigned to Arm(s): K2CG chewing gum (20 mg chitosan) | Intervention Type: OTHER; Name: K2CG chewing gum (60mg chitosan); Assigned to Arm(s): K2CG chewing gum (60 mg chitosan)
D: Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: KRX-0502 (Ferric Citrate); Type: EXPERIMENTAL; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Intervention Type: DRUG; Name: ferric citrate, ca acetate, sevelamer carbonate, placebo; Assigned to Arm(s): Active Control, KRX-0502 (Ferric Citrate), Placebo

Answer: A